Longevity
Sana Biotech heads to EASD with diabetes cell therapy update
Company to spotlight clinical progress on immune-evasive cell therapy that could reshape regenerative medicine for type 1 diabetes. What if the biggest breakthrough in treating type 1 diabetes isn’t replacing the cells that make insulin but convincing the body to simply leave them alone? For many people living with type 1 diabetes (T1D), replacing lost […] The post Sana Biotech heads to EASD with diabetes cell therapy update appeared first on Longevity.Technology .
This story was reported by Longevity.Technology. EUROPES curates Europe's most relevant coverage — read the full report at the original source.
Read full coverage at Longevity.Technology →